AUTHOR=Itoh Arata , Ortiz Lorenzo , Kachapati Kritika , Wu Yuehong , Adams David , Bednar Kyle , Mukherjee Shibabrata , Chougnet Claire , Mittler Robert S. , Chen Yi-Guang , Dolan Laurence , Ridgway William M. 

TITLE=Soluble CD137 Ameliorates Acute Type 1 Diabetes by Inducing T Cell Anergy

JOURNAL=Frontiers in Immunology

VOLUME=10

YEAR=2019

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.02566

DOI=10.3389/fimmu.2019.02566

ISSN=1664-3224

ABSTRACT=<p>We show here that soluble CD137 (sCD137), the alternately spliced gene product of <italic>Tnfsfr9</italic>, effectively treats acute type 1 diabetes (T1D) in nonobese diabetic (NOD) mice. sCD137 significantly delayed development of end-stage disease, preserved insulin+ islet beta cells, and prevented progression to end-stage T1D in some mice. We demonstrate that sCD137 induces CD4+ T cell anergy, suppressing antigen-specific T cell proliferation and IL-2/IFN-γ secretion. Exogenous IL-2 reversed the sCD137 anergy effect. sCD137 greatly reduces inflammatory cytokine production by CD8 effector memory T cells, critical mediators of beta cell damage. We demonstrate that human T1D patients have decreased serum sCD137 compared to age-matched controls (as do NOD mice compared to NOD congenic mice expressing a protective <italic>Tnfsfr9</italic> allele), that human sCD137 is secreted by regulatory T cells (Tregs; as in mice), and that human sCD137 induces T cell suppression in human T cells. These findings provide a rationale for further investigation of sCD137 as a treatment for T1D and other T cell–mediated autoimmune diseases.</p>